Adoptive cell therapy (ACT), the autologous or allogenic transplant of immune cells, is providing new hope in the ongoing battle against cancer. However, the path to harnessing the full potential of these therapies remains challenging, from understanding the intricate dynamics of individual cells to optimizing their therapeutic efficacy. Bruker’s Beacon® Platform emerges as a transformative …
Cellular Analysis Blog
Explore Cell Therapy Articles
Latest
Navigating TCR-T Therapy: Insights from Single-Cell Proteomic Analysis
In cancer immunotherapy, TCR-T based cell therapies show promise for addressing specific types of solid tumors; however, variable patient responses and the potential for relapse indicate a need for improvement. A recent study published in Cancer Immunology Research by researchers at UCLA investigates clinical biomarkers for patient response in TCR-T therapy, shedding light on crucial …
Navigating TCR-T Therapy: Insights from Single-Cell Proteomic Analysis Read More »
New eBook: Unveiling a Breakthrough in Cancer Treatment
In the field of oncology, chimeric antigen receptor (CAR)-T cell therapy is a focal point of innovative research that has the potential to revolutionize cancer treatment. In our new eBook, “Creating the World’s First On-Chip CAR Library: How Cutting Edge Thinking and Technology Are Transforming the Cancer Treatment Landscape,” we offer you the opportunity to …
New eBook: Unveiling a Breakthrough in Cancer Treatment Read More »
Upcoming Webinar: How to Speed Up Cell Therapy Development Processes
Although cellular immunotherapy can achieve good outcomes, only a small proportion of cancer patients are being treated via this approach, with extremely long waitlists. Furthermore, applying centralized manufacturing workflows to individualized products results in complex logistics, creating laborious and non-standardized processes that elevate drug costs. In this upcoming webinar on Thursday, October 26, 10:00-11:00 AM …
Upcoming Webinar: How to Speed Up Cell Therapy Development Processes Read More »
Published in Blood: Unlocking the Potential of CD200R-CD28 Switch for Enhanced CAR-T Therapy in Multiple Myeloma
In a groundbreaking study, researchers at the University of Pennsylvania have identified a novel approach for advancing the effectiveness of CAR-T cell therapy for treating multiple myeloma (MM), a challenging form of cancer. In particular, the study investigates the phenomenon of CAR-T cell suppression, which often leads to relapses in MM patients treated with BCMA-specific …
Advancing Cancer Immunotherapy with Optofluidics and Proteomic Barcoding Technologies
The convergence of optofluidics and proteomic barcoding technologies marks a significant milestone in the evolution of cancer immunotherapy research. These cutting-edge tools empower scientists to unravel the complexities of immune responses, cellular behaviors, and functional proteomics with unprecedented speed and precision. As the pursuit of personalized medicine gains momentum, these technologies offer promise in guiding …
Advancing Cancer Immunotherapy with Optofluidics and Proteomic Barcoding Technologies Read More »
CAR-TCR Spotlight: Visit Us at Booth #C31 to Learn More About How Single-Cell Functional Analysis is Advancing Cell Therapy Research
Bruker Cellular Analysis is looking forward to attending the 8th CAR-TCR Summit, the world’s pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types. From August 29 – September 1st in Boston, MA, this conference will feature groundbreaking presentations, panel discussions, and poster sessions focused on CAR-T and …
Precision Medicine is Now More Accessible and Affordable: Introducing The Beacon Quest™ Optofluidic System
As next-generation precision medicine grows, so does the need for broader accessibility to cutting-edge technologies. To meet this demand, Bruker Cellular Analysis has introduced the Beacon Quest™ optofluidic system, a two-chip optofluidic system that features Opto T Cell Profiling workflows for immunotherapy translational research, Opto Plasma B Discovery workflow and Opto Memory B Discovery workflows …
The Power of IsoCode® Single-Cell Secretome Platform in Characterizing Adoptive Cell Therapies
Cancer treatments have come a long way in recent years, and adoptive cell therapy (ACT) is at the forefront of this transformation. With promising therapies such as CAR-T, CAR-NK, TCR-T and TIL, ACT is providing renewed hope and improved outcomes for patients. Still, there’s more work to be done. To fully comprehend the potency of …
Unlock the Phenome